source
- Novo presents low-dose CagriSema data showing competitiveness ahead of approval decisionNovo used its capital markets day in London to unveil new low-dose data for its experimental metabolic therapy CagriSema. The data indicated that CagriSema performed comparably to Eli Lilly's Moun…
- Telix to acquire Germany's ITM for $1.65 billion, aiming to dominate radiopharmaceutical marketTelix, an Australian radiopharmaceutical diagnostics company, announced it will purchase German developer ITM in a cash transaction valued at $1.65 billion upfront. The agreement gives Telix the o…